Delivery of Full Dose CHOP Chemotherapy to Elderly Patients with Aggressive Non-Hodgkin's Lymphoma without G-CSF Support

References

• Levin P. H., Hoover R. The emerging epidemic of non-Hodgkin's lymphoma: Current knowledge regarding etiological factors. Cancer Epidemiol Biomark Prey 1992; 1: 515–517
   PubMed Web of Science ®Google Scholar
• Devessa S. S., Fears T. Non-Hodgkin's lymphoma time trends: United States and International Data. Cancer Res 1992; 52%(suppl)5432S, -5440S.
   PubMed Web of Science ®Google Scholar
• Fisher R. I., Gaynor E. R., Dahlberg S., et al. A phase III comparison of CHOP vs m-BACOD vs ProM-ACE-CytoBOM vs MACOP-B in patients with intermediate or high-grade non-Hodgkin's lymphoma: Results of SWOG-8516 (Intergroup 0067). Annals of Oncology 1994; 5: S91–S95
   PubMed Web of Science ®Google Scholar
• D'amore F., Brincker H., Christensen B. E., et al. Non-Hodgkin's lymphoma in the elderly. Annals of Oncology 1992; 3: 379–386
   PubMed Web of Science ®Google Scholar
• Shipp M. A., et al. A Predictive Model for Aggressive non-Hodgkin's Lymphoma—The International non-Hodgkin's Lymphoma Prognostic Factor Project. New England Journal of Medicine 1993; 329: 987–994
   PubMed Web of Science ®Google Scholar
• Ansell S. M., Falkson G., van der Merwe R., et al. Chronological age is a multifactorial prognostic variable in patients with non-Hodgkin's lymphoma. Annals of Oncology 1992; 3: 45–50
   PubMed Web of Science ®Google Scholar
• Orlandi E., Lazzarino M., Brusamolino E., et al. Non-Hodgkin's lymphoma in the elderly: the impact of advanced age on therapeutic options and clinical results. Haematologica 1991; 76: 204–208
   PubMed Web of Science ®Google Scholar
• Vose J. M., Armitage J. O., Weisenburger D. D., et al. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. Journal of Clinical Oncology 1988; 6: 1838–1844
   PubMed Web of Science ®Google Scholar
• Armitage J. O., Potter J. F. Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly. L Am Geriatr Soc 1984; 32: 269–273
   PubMed Web of Science ®Google Scholar
• Tirelli U., Zagonel V., Serraino D., et al. Non-Hodgkin's lymphoma in 137 patients aged 70 years or older: a retrospective European organization for research and treatment of cancer lymphoma group study. Journal of Clinical Oncology 1988; 6: 1708–1713
   PubMed Web of Science ®Google Scholar
• Meyer R. M., Browman G. P., Samosh M. L., et al. Randomized phase II comparison of standard CHOP with weekly chop in elderly patients with non-Hodgkin's lymphoma. Journal of Clinical Oncology 1995; 13: 2386–2393
   PubMed Web of Science ®Google Scholar
• Sonneveld P., Hop W., Mulder A. H., et al. Full-dose chemotherapy for non-Hodgkin's lymphoma in the elderly. Seminars in Hematology 1994; 31: 9–12
   PubMed Web of Science ®Google Scholar
• Dixon D. O., Neilan B., et al. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma. Journal of Clinical Oncology 1986; 4: 295–305
   PubMed Web of Science ®Google Scholar
• Ansell S. M., Falkson G. A phase II trial of a chemotherapy combination in elderly patients with aggressive lymphoma. Annals of Oncology 1993; 4: 172–175
   PubMed Web of Science ®Google Scholar
• Bertini M., Freilone R., Vitolo U., et al. P-VEBEC: A new 8-weekly schedule with or without rG-CSF for elderly patients with aggressive non-Hodgkin's lymphoma (NHL). Annals of Oncology 1994; 5: 895–900
   PubMed Web of Science ®Google Scholar
• Bessell E. M., Coutts A., Fletcher J., et al. Non-Hodgkin's lymphoma in elderly patients: a phase II study of MCOP chemotherapy in patients aged 70 years or over with intermediate or high-grade histology. European Journal of Cancer 1994; 30A: 1337–1341
   PubMed Web of Science ®Google Scholar
• Caracciolo E, Petrini M., Capochiani E., et al. Alternate chemotherapy regimen (P-VABEC) for intermendi-ate and high-grade non-Hodgkin's lymphoma of the middle aged and elderly. Hematological Oncology 1994; 12: 185–192
   PubMed Web of Science ®Google Scholar
• Goss P. E., Burkes R., Rudinskas L., et al. Pred-nisone, oral etoposide and novantrone for treatment of non-Hodgkin's lymphoma: a preliminary report. Seminars in Hematology 1994; 31: 23–29
   PubMed Web of Science ®Google Scholar
• Kitamura K., Fumimaro T. THP-COP Therapy for non-Hodgkin's lymphoma in the elderly. Am J Clin Oncol 1990; 13%(suppl 1)S15–19
   PubMed Web of Science ®Google Scholar
• Liang R., Todd D., Chan T. K., et al. COPP chemotherapy for elderly patients with intermediate and high grade non-Hodgkin's lymphoma. Hematological Oncology 1993; 11: 43–50
   PubMed Web of Science ®Google Scholar
• Martelli M., Guglielmi C., Coluzzi S. e., et al. A prospective study of a new weekly chemotherapy regimen for elderly aggressive non-Hodgkin's lymphoma. Journal of Clinical Oncology 1993; 11: 2362–2369
   PubMed Web of Science ®Google Scholar
• McMaster M. L., Johnson D. H., Greer J. P. e. a. A brief-duration combination chemotherapy for elderly patients with poor-prognosis non-Hodgkin's lymphoma. Cancer 1991; 67: 1487–1492
   PubMed Web of Science ®Google Scholar
• Novitzky N., King H. S., Johnson C., et al. Treatment of agressive non-Hodgkin's lymphoma in the elderly. American Journal of Hematology 1995; 49: 103–108
   PubMed Web of Science ®Google Scholar
• O'Reilly S. E., Klimo P., Connors J. M. Low-dose ACOP-B and VABE: Weekly chemotherapy for elderly patients with advanced-stage diffuse large-cell lymphoma. Journal of Clinical Oncology 1991; 9: 141–747
   Web of Science ®Google Scholar
• O'Reilly S. E., Connors J. M., Howdle S., et al. In search of an optimal regiman for elderly patients with advanced stage diffuse large cell lymphoma: Results of a phase II study of P/DOCE chemotherapy. Journal of Clinical Oncology 1993; 11: 2250–2257
   PubMed Web of Science ®Google Scholar
• Salvagno L., Contu A., Bianco A., et al. A combination of mitoxantrone, etoposide and prednisone in elderly patients with non-Hodgkin's lymphoma. Annals of Oncology 1992; 3: 833–837
   PubMed Web of Science ®Google Scholar
• Sonneveld P., Sonneveld J. J. M. Full dose chemotherapy in elderly patients with non-Hodgkin's lymphoma: a feasibility study using a mitoxantrone containing regimen. Br J Cancer. 1990; 62: 105–108
   PubMed Web of Science ®Google Scholar
• Tigaud J. -D., Demolombe S., Bastion Y., et al. lfos-famide continuous infusion plus etoposide in the treatment of elderly patients with aggressive lymphoma: a phase II study. Hematolozical Oncology 1991; 9: 225–233
   PubMed Web of Science ®Google Scholar
• Tirelli U., Carbone A., Zagonel V., et al. Non-Hodgkin's lymphomas in the elderly: Prospective studies with specifically devised chemotherapy regimens in 66 patients. Eur J Cancer Clin Oncol 1987; 23: 535–540
   PubMedGoogle Scholar
• Tirelli U., Zagonel V., Semino S. R., et al. A prospective study of a new combination chemotherapy regimen in patients older than 70 years with unfavourable non-Hodgkin's lymphoma. Journal of Clinical Oncolom 1992; 10: 228–236
   PubMed Web of Science ®Google Scholar
• Zinzani P. L., Bendandi M., Gherlinzoni F., et al. VNCOP-B regimen in the treatment of high-grade non-Hodgkin's lymphoma in the elderly. Haematologica 1993; 78: 378–382
   PubMed Web of Science ®Google Scholar
• Hrymuk W. A. The importance of dose intensity in outcome of chemotherapy. Important advances in oncology 1988., V. J. DeVita, S. Hellman, S. A. Rosenberg. Lippincog, Philadelphia 1988; 121–141
   Google Scholar
• Kaplan E. L., Meier P. Nonparametric estimation from incomplete observations. J. Amer Stat. Assoc. 1958; 53: 457–481
   Web of Science ®Google Scholar
• Epelbaum R., Haim N., Leviov M., et al. Full dose CHOP chemotherapy in elderly patients with non-Hodgkin's lymphoma. Acta Oncologica. 1995; 34: 87–91
   PubMed Web of Science ®Google Scholar
• Grogan L., Corbally N., Dervan P. A., et al. Comparable prognostic factors and survival in elderly patients with aggressive non-Hodgkin's lymphoma treated with standard-dose Adriamycin-based regimens. Annals of Oncology 1994; 5%(Suppl. Z), S47–S51.
   Google Scholar
• Golde DW, Neidhart JA, Scadden DT, et al. The rational use of hematopoietic growth factors. Proc Am Soc Hem 1995; 37: 112–118
   Google Scholar